Surface enhanced laser desorption ionization spectrometry reveals biomarkers for drug treatment but not dose

Here we describe the use of SELDI‐MS to detect dose‐dependent peptide changes in plasma from mice treated with vehicle or rosiglitazone at one of two doses (10 and 30 mg/kg). SELDI features differentiating spectra from the three conditions were found and used to train classifiers. Samples treated wi...

Full description

Saved in:
Bibliographic Details
Published in:Proteomics (Weinheim) 2006-04, Vol.6 (7), p.2101-2107
Main Authors: Paweletz, Cloud P., Wiener, Matthew C., Sachs, Jeffrey R., Meurer, Roger, Wu, Margaret S., Wong, Kenney K., Yates, Nathan A., Hendrickson, Ronald C.
Format: Article
Language:English
Subjects:
Analytical, structural and metabolic biochemistry
Animals
Biological and medical sciences
Biomarker
Biomarkers - blood
Dose-Response Relationship, Drug
Fundamental and applied biological sciences. Psychology
Male
Mice
Miscellaneous
Models, Biological
Peptides - analysis
Peptides - blood
Peptides - chemistry
Proteins
Proteomic classifier
Reproducibility of Results
SELDI
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
Thiazolidinediones - administration & dosage
Thiazolidinediones - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Here we describe the use of SELDI‐MS to detect dose‐dependent peptide changes in plasma from mice treated with vehicle or rosiglitazone at one of two doses (10 and 30 mg/kg). SELDI features differentiating spectra from the three conditions were found and used to train classifiers. Samples treated with vehicle could be reliably distinguished from samples treated with either dose, but samples treated with the different doses could not be reliably distinguished from one another. We conclude that while SELDI‐TOF mass spectra can be used to distinguish treated from untreated samples, the reproducibility and information content of SELDI‐TOF are currently not sufficient as a pharmacodynamic readout to distinguish between mice treated with 10 or 30 mg/kg of rosiglitazone. This raises more general questions about whether SELDI's sensitivity is sufficient for detecting dose‐dependent changes in plasma.
ISSN:1615-9853
1615-9861
DOI:10.1002/pmic.200500569